Colorectal Cancer | Specialty

MCRC: Sequencing Based on RAS Status and Tumor Sidedness

February 8th 2020

MCRC: Molecular Testing

February 8th 2020

Importance of Tumor Sidedness in mCRC

February 8th 2020

Predictive Markers for mCRC

February 8th 2020

Molecular Testing for Metastatic CRC in 2020

February 8th 2020

Dr. Weinberg on the Role of Cetuximab in Metastatic CRC

February 7th 2020

Benjamin Weinberg, MD, discusses the role of cetuximab in treating metastatic colorectal cancer.

Dr. Putcha on the Use of Blood-Based Screening Assays in CRC

February 5th 2020

Girish Putcha, MD, PhD, discusses the use of blood-based screening assays in colorectal cancer (CRC).

Regorafenib/TAS-102 Induces Clinically Meaningful DCR in Refractory Metastatic CRC

January 27th 2020

Third-line treatment of patients with metastatic colorectal cancer using regorafenib plus oral fluoropyrimidine TAS-102 provides clinically meaningful disease control with toxicities consistent with the safety profiles of either agent, according to data from the phase I dose-escalation trial REMETY presented at the 2020 Gastrointestinal Cancers Symposium.

High Responses Observed With Avelumab Added to Regimen for Metastatic Colorectal Cancer Does Not Translate to PFS

January 26th 2020

A regimen of avelumab and cetuximab plus oxaliplatin, leucovorin, and 5-fluorouracil in patients with RAS/BRAF-wildtype metastatic colorectal cancer induced a very high response rate but did not meet its primary progression-free survival end point.

Kopetz Highlights Improved QoL, Efficacy With Encorafenib Regimens in BRAF+ mCRC

January 25th 2020

Scott Kopetz, MD, PhD, FACP, sheds light on encorafenib triplet and doublet options for patients with BRAF V600E–mutant metastatic colorectal cancer and other novel regimens under investigation.

Dr. Morris on Optimizing CRC Treatment Based on Oligometastatic Status

January 25th 2020

Van Morris, MD, discusses research around treatment for patients with unresectable colorectal cancer.

Investigators Test Breakthrough-Designated Triplet in First-Line CRC

January 17th 2020

Investigators hope to answer a potentially paradigm-changing question in the phase II ANCHOR-CRC study (NCT03693170) of BRAF V600E–mutant colorectal cancer (CRC): Can the benefit observed with a targeted triplet in latestage disease extend to the first line?

Molecular Testing for Colon Cancer Falls Far Short of the Guidelines

January 16th 2020

Between 2013 and 2017, just 40% of patients with metastatic colon cancer received guideline-recommended biomarker testing that could have improved treatment decisions, according to findings from a retrospective study. Results also showed that adherence to evidence-based recommendations for genotyping was poor in academic and community settings alike.

Dr. Lockhart on Strategies for Targeting the RAS/RAF/MEK/ERK Pathway in CRC

January 14th 2020

A. Craig Lockhart, MD, MHS, professor and associate director for Regional and Strategic Clinical Research Affiliations, Sylvester Comprehensive Cancer Center, University of Miami Health System, discusses investigational strategies targeting the RAS/RAF/MEK/ERK pathway in colorectal cancer (CRC).

Role of Immunotherapy Agents Grows in Metastatic Colorectal Cancer

January 11th 2020

The standard of care in the second line for patients with mismatch repair–deficient metastatic colorectal cancer has shifted to favor therapy utilizing immunotherapeutic agents, according to Howard Hochster, MD.

Expert Highlights Immunotherapy Combo Strategies in Relapsed/Refractory CRC

January 10th 2020

A. Craig Lockhart, MD, MHS, discusses ongoing developments and the future of immunotherapy in colorectal cancer.

Dr Weinberg on Varying Treatment Options in Metastatic Colorectal Cancer

January 9th 2020

Benjamin Weinberg, MD, discusses varying treatment options for patients with metastatic colorectal cancer.

Dr. Vulfovich on Molecular Testing in Colorectal Cancer

January 7th 2020

Michel Vulfovich, MD, discusses molecular testing in colorectal cancer.

Dr. Lockhart on Next Steps for Regorafenib and TAS-102 in mCRC

January 4th 2020

A. Craig Lockhart, MD, MHS, professor, associate director for Regional and Strategic Clinical Research Affiliations, Sylvester Comprehensive Cancer Center, University of Miami Health System, discusses next steps for regorafenib (Stivarga) and TAS-102 (trifluridine/tipiracil; Lonsurf) in metastatic colorectal cancer (mCRC).

Dr. Vulfovich on Broad Molecular Profiling in mCRC

December 20th 2019

Michel Vulfovich, MD, medical director, Sickle Cell Disease and Gynecology Oncology programs, Memorial Healthcare System, discusses the utility of broad molecular profiling in metastatic colorectal cancer (mCRC).